Sirona Biochem (TSE:SBM) has released an update.
Sirona Biochem is set to enter the anti-aging market in early 2025 with its first cosmeceutical serum, GlycoProteMim™, which promises rejuvenating benefits. The company has completed the serum’s formulation, is finalizing packaging, and is navigating regulatory steps. With partnerships in key global markets and potential profitability by 2025, Sirona Biochem is gearing up for a significant commercial leap.
For further insights into TSE:SBM stock, check out TipRanks’ Stock Analysis page.
